SCHEMBL720703

SCHEMBL720703

Cc1c(C=O)sc2cccnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.41
NPC1 O15118 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LIMK1 P53667 2/20 0.41
CLK1 P49759 1/20 0.38
CYP2A6 P11509 2/20 0.37
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
IDO1 P14902 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ERN1 O75460 1/20 0.36
CCR1 P32246 3/20 0.35
CCR8 P51685 3/20 0.35
LMNA P02545 4/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
ESR1 P03372 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20041730 0.78 NPC1 (0.37) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL13763321 0.76 HSP90AA1 (0.48) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL19699885 0.73 LIMK1 (0.49) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL718727 0.72 CYP2A6 (0.44) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL157274 0.71 TUBB4A (0.48) NPC1CYP2A6KDM4EMEN1KMT2A
SCHEMBL10033652 0.70 HSP90AA1 (0.42) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL5776212 0.70 LIMK1 (0.69) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL10054253 0.70 LIMK1 (0.57) HSP90AA1NPC1L3MBTL1LIMK1CLK1
SCHEMBL1811307 0.68 LIMK1 (0.50) NPC1L3MBTL1LIMK1KDM4EMEN1
SCHEMBL19732034 0.68 LIMK1 (0.37) HSP90AA1NPC1L3MBTL1LIMK1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP HSP90AA1 2403/4885NPC1 902/4885L3MBTL1 4088/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP HSP90AA1 2403/4885NPC1 902/4885L3MBTL1 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.